🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CONGRESS | #EHA25 | PRESENTATION Benajiba Lina @hopsaintlouis @univ_paris @inserm speaks on clonal selection in #MPN, explaining that some mutations have prognostic impact on survival, thrombosis, and AML progression. ▪️ In a 36-gene panel, clonal evaluation was associated with

CONGRESS | #EHA25 | PRESENTATION Immune therapy in #MPN was discussed by FlorianHeidel, Hannover Medical School, including: ▪️ mutant calreticulin as a neoantigen ▪️ the potential of checkpoint inhibitors, particularly given alterations in the global signalling landscape

CONGRESS | #EHA25 | PRESENTATION Susan Robinson Sue Robinson Guy's and St Thomas' shares thoughts on fertility and pregnancy in #MPN. Birth rates are reduced in MPN vs control, although higher than previously thought, with increased low birth weight and pre-term delivery rates; JAK2 mutation may

CONGRESS | #EHA25 | PRESENTATION Vikas Gupta Vikas Gupta Princess Margaret Cancer Centre discusses management of accelerated and blast phase #MPN (MPN-AP/BP). Genetic profile of blast phase MPN different to de novo AML, little clinical trial data available as patients not usually eligible.

CONGRESS | #EHA2025 | PRESENTATION John Mascarenhas, Icahn School of Medicine at Mount Sinai shares preliminary results from the dose-escalation cohorts of the phase I INCA33989-101 and -102 trials evaluating INCA33989, a novel mutant calreticulin-specific monoclonal antibody therapy, in patients with

CONGRESS | #EHA2025 | PRESENTATION Stefan Constantinescu, Stefan Constantinescu, Ludwig Cancer, presents preclinical findings on the transformation of MPN to sAML using a diverse spectrum of clinically relevant TP53 mutations. p53 mutants in sAML increase the STAT5 transcriptional

CONGRESS | #EHA2025 | PRESENTATION Norman Fultang, Prelude Therapeutics, discusses the discovery of a first-in-class CALR-targeted pADCs that selectively target mutant CALR-expressing cells. There was a selective, potent dose-dependent inhibition of growth of CALR mutant cells,

CONGRESS | #EHA2025 | PRESENTATION Beth Psaila, Beth Psaila, MRC WIMM, gives a talk about a mutCALR×CD3 antibody (INCA035784) binds mutant cells, activates T cells for targeted cancer cell elimination. Potent activity towards type 1 and type 2 mutCALR with in vivo efficacy in

CONGRESS | #EHA2025 | PRESENTATION Samantha Tauchmann, Samantha Tauchmann, OHSU Knight Cancer Institute, discusses the role of SETBP1 mutations in orchestrating transcriptional programs that drive leukemogenesis in myeloid malignancies. · Increased self-renewal · Promotes granulocytic progenitor

CONGRESS | #EHA2025 | PRESENTATION Rosalin Cooper, University of Oxford, talks about spatial transcriptomic analysis of novel microenvironmental immune signatures and stromal remodelling associated with fibrosis in myeloproliferative neoplasia. · Bone marrow has distinct peritrabecular

CONGRESS | #EHA2025 | POSTER Haifa Kathrin Al-Ali unimedhal presented a post-hoc analysis of the phase II ACE-536-MF-001 (MF-001) study exploring the relationship between Hb level and anemia-related QoL in non-transfusion dependent patients with MF treated with luspatercept (n

CONGRESS | #EHA2025 | POSTER Francesca Palandri Università di Bologna shares findings from a subgroup analysis of the phase III SIMPLIFY-1 trial (N = 432) investigating the impact of SVR35 and TI on OS in patients with JAKi-naïve #myelofibrosis and anemia with momelotinib (n = 86) vs

CONGRESS | #EHA2025 | POSTER Tiziano Barbui FROM Fondazione per la Ricerca Ospedale di Bergamo presented long-term follow-up findings from the Low-PV trial comparing fixed dose ropeginterferon alfa-2b 100 µg every two weeks to phlebotomy-only in low-risk patients with polycythemia vera. Low-dose ropeg α-2b provided

CONGRESS | #EHA2025 | POSTER Jihyun Song presented findings from a study examining the molecular determinants of resistance to ropeginterferon alpha-2B in patients with PV (n = 34) and ET (n = 16). The findings indicate that non-responsiveness to ropeg is associated with

CONGRESS | #EHA2025 | POSTER Elisa Rumi Elisa Rumi presented findings from a study of germline variants in patients with #MPN with early onset or familial history (N = 313). Germline CHEK2 variants were identified in 2.2% of cases with young and familial MPN. The association

CONGRESS | #EHA2025 | POSTER Martina Crysandt presented findings from a study designed to elucidate the cellular complexity of the MF bone marrow niche with a focus on regulation of mutated hematopoietic stem cells by immune cells and the non-hematopoietic stromal compartment.

🚨 NEWS 🚨 U.S. FDA grants fast track designation to nuvisertib, an oral, investigational, highly selective PIM1 kinase inhibitor, for the treatment of patients with intermediate or high-risk #myelofibrosis Read more: loom.ly/rhBmSLo #MPN #MPNsm #MedNews

Stay up to date with the latest developments in myeloproliferative neoplasms with our coverage from the #EHA2025 Congress, June 12–15, Milan, IT and online. loom.ly/A4LqHd0 #MPN #mpnsm #EHA2025

During #EHA2025, Francesca Palandri presented a subgroup analysis of patients with MF and baseline anemia in SIMPLIFY-1. Dual spleen and TI responses were higher with momelotinib (27%) vs ruxolitinib (7%). Watch here: loom.ly/u87xFdw #MPN #MPNsm #MedNews #MedEd